GlassScriptPhysician profile
Timothy M Sowerby
NPI 1063475952
$4,753.72
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $260 · 2021: $1,124 · 2022: $1,662 · 2023: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,471.94 | 2019-2023 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $678.05 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $605.34 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $343.98 | 2019-2023 | |
| Janssen Biotech, INC. | $328.70 | 2019-2023 | Stelara, Simponi Aria, Remicade |
| Pfizer INC. | $236.86 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $213.03 | 2021-2022 | |
| Celgene Corporation | $193.10 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $163.94 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $75.26 | 2019-2022 | |
| Ardelyx, INC. | $55.85 | 2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $49.32 | 2022-2023 | Dupixent |
| Genzyme Corporation | $49.13 | 2022 | |
| Braintree Laboratories, INC. | $47.27 | 2019-2022 | |
| Shionogi INC | $41.37 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.64 | 2022 | |
| Apollo Endosurgery US INC | $28.27 | 2019 | |
| Portola Pharmaceuticals, LLC | $23.95 | 2019 | |
| Intercept Pharmaceuticals, INC. | $21.95 | 2019 | |
| Endo Pharmaceuticals INC. | $21.03 | 2019 | |
| Merck Sharp & Dohme LLC | $19.58 | 2020 | |
| Redhill Biopharma INC. | $15.99 | 2022 | |
| Allergan, INC. | $15.26 | 2019 | |
| Qol Medical, LLC | $13.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Sowerby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.